Glycation amplifies lipoprotein(a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells

Atherosclerosis

Volumn 150, Issue 2, 2000, Pages 299-308

  Zhang, Jianying ^a   Ren, Song ^a   Shen, Garry X ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Aminoguanidine; Antioxidants; Glycated lipoprotein(a); Plasminogen activator inhibitor 1; Tissue type plasminogen activator; Vascular endothelial cells

Indexed keywords

LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HUMAN CELL; LIPID OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; VASCULAR ENDOTHELIUM;

BIOLOGICAL MARKERS; BLOTTING, NORTHERN; CARDIOVASCULAR DISEASES; CELLS, CULTURED; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FIBRINOLYSIS; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS, LDL; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRECIPITIN TESTS; RNA, MESSENGER; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0034081217     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00381-0     Document Type: Article

References (66)

1. Berg K. Lp(a) lipoprotein: a review. Chem Phys Lipids. 67-68:1994;9-16.
2. Lenzi S., Scanu A., DeCaterina R. Lipoprotein(a) as an athero-thrombotic risk factor: epidemiological evidence and possible pathologenic mechanism. G Ital Cardiol. 126:1996;1203-1225.
3. Rath M.S., Niendorf A., Reblin T., Dietel M., Krebber H.J., Beisiegel U. Detection and qualification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 9:1989;579-592.
4. Cushing G.L., Gaubatz J.W., Nava M.L., Burdick B.J., Bocan T.M., Guyton J.R., Weibacecher D., DeBakey M.E., Lawrie G.M., Morrisett J.D. Quantitation and localization of apolipoproteins[a] and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis. 9:1989;593-603.
5. Steiner G. Dyslipoproteinemia in diabetes. Clin Invest Med. 18:1995;282-287.
6. Doucet C., Huby T., Ruiz J., Chapman M.J., Thillet J. Non-enzymatic glycation of lipoprotein(a) in vitro and in vivo. Atherosclerosis. 118:1995;135-143.
7. Miles L.A., Fless G.M., Levin E.G., Scanu A.M., Plow E.F. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 339:1989;301-303.
8. Hajjar K.A., Gavish D., Breslow J.L., Nachinann R.L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 339:1989;303-305.
9. Fearnly G.R., Chakrabartl R., Avis P.R. Blood fibrinolytic activity in diabetes mellitus and its bearing on ischaemic heart disease and obesity. Br Med J. 1:1963;921-923.
10. Auwerx J., Bouillon R., Collen D., Geboers J. Tissue-type plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis. 8:1988;68-72.
11. Juhan-Vague I., Roul C., Alessi M.C., Ardissone J.P., Heim M., Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulin. Thromb Haemost. 61:1989;370-373.
12. Carmassi F., Morale M., Puccetti R., DeNegri F., Monzani F., Navalesi R., Mariani G. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res. 67:1992;643-654.
13. Schneider D.J., Nordt T.K., Sobel B.E. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes. 41:1992;890-895.
14. Meiellon M., Boeri D., Podesta F., Cagliero E., Vichi M., Odetti P., Adezati L. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes. 41:1992;1009-1015.
15. Kollros P.R., Konkle B.A., Ambarian A.P., Henrikson P. Plasminogen activator inhibitor-1 expression by brain microvessel endothelial cells is inhibited by elevated glucose. J Neurochem. 63:1994;903-909.
16. Stiko-Rahm A., Wiman B., Hamsten A., Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis. 10:1990;1067-1073.
17. Tremoli E., Camera M., Maderna P., Sironi L., Prati L., Colli S., Piovella F., Bernini F., Corsini A., Mussoni L. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs: An LDL receptor-independent phenomenon. Arterioscler Thromb. 13:1993;338-346.
18. Latron Y., Chautan M., Anfosso F., Alessi M.C., Lafont H., Juhan-Vague I. Stimulating effect of oxidized low density lipoprotein on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb. 11:1991;182-189.
19. Chauton M., Latron Y., Anfosso F., Alessi M.C., Lafont H., Juhan-Vague I., Nalbone G. Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low density lipoproteins in human endothelial cells. J Lipid Res. 34:1993;101-110.
20. Kugiyama K., Sakamoto T., Ohgushi M., Ogawa H., Horiguchi M., Yasue H. Transferable lipids in oxidized low density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue plasminogen activator release from endothelial cells. Circ Res. 73:1993;335-343.
21. Kaneko T., Wada H., Wakita Y., Minamikawa K., Nakase T., Nakase T., Mori Y., Deguchi K., Shirakawa S. Enhanced tissue factor activity and plasminogen activator inhibitor-1 antigen in human umbilical vein endothelial cells incubated with lipoproteins. Blood Coagulation Fibrinol. 5:1994;385-392.
22. Schneider D.J., Sobel B.E. Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very low density lipoproteins and fatty acids. Coronary Artery Dis. 7:1996;813-817.
23. Sironi L., Mussoni L., Prati L., Baldassarre D., Camera M., Banfi C., Tremoli E. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol. 16:1996;89-96.
24. Levin E.G., Miles L.A., Fless G.M., Scanu A.M., Baynham P., Curtiss L.K., Curtiss L.K., Plow E.F. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb. 14:1994;438-441.
25. Etingin O.R., Hajjar D.P., Hajjar K.A., Harpel P.C., Nachinann R.L. Lipoprotein(a) regulates Plasminogen Activator Inhibitor-1 Expression in Endothelial Cells. J Biol Chem. 266:1991;2459-2465.
26. Ren S., Man R.Y.K., Angel A., Shen G.X. Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor-1 in cultured vascular endothelial cells. Atherosclerosis. 128:1997;1-10.
27. Kobayashi K., Watabnabe J., Umeda F., Nawata H. Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocrinol J. 42:1995;461-465.
28. Zhang J.Y., Ren S., Sun D., Shen G.X. Influence of glycation on LDL-induced generation of fibrinolytic regulators from vascular endothelial cells. Arterioscler Thromb Vasc Biol. 18:1998;1140-1148.
29. Schumaker V.N., Puppione D.L. Sequential floatation ultracentrifugation. Methods Enzymol. 128:1986;155-169.
30. Snyder M.L., Polacek D., Scanu A.M., Fless G.M. Comparative binding and degradation of lipoprotein(a) and low density lipoprotein by human monocyte-derived macrophages. J Biol Chem. 267:1992;339-346.
31. Shen G.X., Mymin D., Dembinski T., Krahn A., Angel A. Polymorphism and peripheral levels of apolipoprotein(a) in polygenic hypercholesterolemia and combined hyperlipidemia. Clin Invest Med. 18:1995;33-41.
32. Ren S., Cockell K.A., Fenton J.W.II, Angel A., Shen G.X. G proteins and phospholipase C mediate thrombin-induced generation of plasminogen activator inhibitor-1 from vascular smooth muscle cells. J Vasc Res. 34:1997;82-89.
33. Chirgwin J.M., Pryzbyla A.E., MacDonald R.J., Rutter W.J. Isolation of biological active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:1979;5294-5299.
34. George R., Barbar D.L., Schneider W.J. Characterization of the chicken oocyte receptor for low and very low density lipoproteins. J Biol Chem. 262:1987;16838-16847.
35. Krawczuk-Rybak M., Wojtowicz J., Urban M. State of lipid metabolism in children and adolescents with insulin-dependent diabetes. I. Evaluation of lipoprotein (A) behaviour in children and adolescents with insulin-dependent diabetes. Endokrynol-Pol. 42:1991;437-445.
36. Irish A.B., Simons L.S., Simons J. Lipoprotein(a) concentration in diabetes: relationship to proteinuria and diabetes control. Aust NZ J Med. 22:1992;329-333.
37. Heller F.R., Jamart J., Honore P., Derue G., Novik V., Galanti L. Serum lipoprotein(a) in patients with diabetes mellitus. Diabetes Care. 16:1993;819-823.
38. Murakami J., Kumasaka K., Kawano K., Murakami T., Hayashi Y., Arakawa Y. Lp(a) serum concentrations in diabetes mellitus. Rinsho-Byori. 42:1992;1273-1278.
39. Groop P.H., Viberti G.C., Elliott T.G., Firedman R., Mackie A., Ehnholm C., Jauhiainen M., Taskinen M.R. Lipoprotein(a) in type 1 diabetic patients with renal disease. Diabet Med. 11:1994;961-967.
40. James R.W., Boemi M., Sirolla C., Amadio L., Fumelli P., Pometta P. Lipoprotein(a) and vascular disease in diabetic patients. Diabetologia. 38:1995;711-714.
41. Gall M.A., Rossing P., Hommel E., Voldsgaard A.I., Andersen P., Nielsen F.S., Dyerberg J., Parving H.H. Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy. Scand J Clin Lab Invest. 52:1992;513-521.
42. Klausen I.C., Schmidt E.B., Lervang H.H., Gerdes L.U., Ditzel J., Faergeman O. Normal lipoprotein(a) concentrations and apolipoprotein(a) isoforms in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest. 22:1992;538-541.
43. Csaszar A., Dieplinger H., Sandholzer C., Karadi I., Juhasz E., Drexel H., Halmos T., Romics L., Patsch J.R., Utermann G. Plasma lipoprotein(a) concentration and phenotypes in diabetes mellitus. Diabetologia. 36:1993;47-51.
44. Ritter M.M., Loscar M., Richter W.O., Schwandt P. Lipoprotein(a) in diabetes mellitus. Clin Chim Acta. 214:1993;45-54.
45. Maser R.E., Usher D., Becker D.J., Drash A.L., Kuller L.H., Orchard T.J. Lipoprotein(a) concentration shows little relationship to IDDM complications in the Pittsburgh epidemiology of diabetes complications study cohort. Diabetes Care. 16:1993;755-758.
46. Taupin J.M., Durlach V., Hassaim M., Gillery P., Jolly D., Boirie Y., Grulet H., Leutenegger M. Lipoprotein(a) and diabetes: relationship based on 224 cases. Diabet Metab. 19:1993;250-256.
47. Martinez M.T., Ramos O., Carretero N., Calvillan M., Gutierrez-Lopez M.D., Cuesta P., Serrano-Rios M. Lipoprotein(a) and other risk factors in children with insulin-dependent diabetes mellitus and children without diabetes. Diabete Metab. 20:1994;522-525.
48. Guerci B., Igau B., Ziegler O., Crea T., Fruchart J.C., Drouin P., Fievet C. Lack of relationship between Lp(a) particle levels and albumin excretion rate in type 1 diabetic patients. Diabete Metab. 20:1994;526-531.
49. Ferrer I., Llopart R., Moyano D., Pavia C., Farre C., Ordonez J. Lipoprotein(a): its concentrations in children with insulin-dependent diabetes mellitus. Med Clin Barc. 104:1995;565-567.
50. Haffner S.M., Framgps M., Williamson J., Santiago J., Valdez R., Aldrete G., Mykkanen L., Gruber K.K., Rainwater D.L. Lp(a) concentrations and phenotypes in children with insulin-dependent diabetes mellitus. Chem Phys Lipids. 67-68:1994;223-231.
51. Wolffenbuttel B.H., Leurs P.B., Sels J.P., Rondas-Colbers G.J., Menheere P.P., Nieuwenhuijzen-Kruseman A.C. Improved blood glucose control by insulin therapy in type 2 diabetic patients has no effect on lipoprotein(a) levels. Diabet Med. 10:1993;427-430.
52. Nakata H., Horita K., Eto M. Alteration of lipoprotein(a) concentration with glycemic control in non-insulin-dependent diabetic subjects without diabetic complications. Metabolism. 42:1993;1323-1326.
53. Heesen B.J., Wolffenbuttel B.H., Leurs P.B., Sels J.P., Menheere P.P., Jackle-Beckers S.E., Niewenhuijzen-Kruseman A.C. Lipoprotein(a) levels in relation to diabetic complications in patients with non-insulin-dependent diabetes. Eur J Clin Invest. 23:1993;580-584.
54. O'Brien T., Nguyen T.T., Harrison J.M., Bailey K.R., Dyck P.J., Kottke B.A. Lipids and Lp(a) lipoprotein (a) levels and coronary artery disease in subjects with non-inuslin-dependent diabetes mellitus. Mayo Clin Proc. 69:1994;430-435.
55. Morisaki N., Yokote K., Tashiro J., Inadera H., Kobayashi J., Kanzaki T., Saito Y., Yoshida S. Lipoprotein (a) is a risk factor for diabetic retinopathy in the elderly. J Am Geriatr Soc. 42:1994;965-967.
56. Ruiz J., Thillet J., Huby T., James R.W., Erlich D., Flandre P., Froguel P., Chapman J., Passa P. Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. Diabetologia. 37:1994;585-591.
57. Hiraga T., Shimada M., Okubo M., Nakanishi K., Kobayashi T., Murase T. Lipoprotein(a) is an independent risk factor for multiple cerebral infarctions. Atherosclerosis. 26:1996;29-32.
58. Miyao M., Araki A., Hattori A., Miyachi T., Inoue J., Horiuchi T., Nalamura T., Ueda S., Nalahara K., Matsushita S., Ito H. Lipoprotein(a) as a risk factor for cardiovascular disease in elderly patients with diabetes. Nippon Ronen Igakkai Zasshi. 34:1997;185-191.
59. Haffner S.M., Morales P.A., Stern M.P., Gruber M.K. Lp(a) concentrations in NIDDM. Diabetes. 41:1992;1267-1272.
60. Velho G., Erlich D., Trupin E., Neel D., Cohen D., Froguel P., Passa P. Lipoprotein(a) in diabetic patients and normoglycemic relatives in familial NIDDM. Diabetes Care. 16:1993;742-747.
61. Kuusi T., Yki-Jarvinen H., Kauppinen-Makelin R., Jauhiainen M., Ehnholm C., Kauppila M., Seppala P., Viikari J., Kujansuu E., Rajala S., Lahti J., Niskanen L., Marjanen T., Salo S., Ryysy L., Tulokas T., Taskinen M.R. Effect of insulin treatment on serum lipoprotein(a) in non-insulin-dependent diabetes. Eur J Clin Invest. 25:1995;194-200.
62. Rainwater D.L., MacCluer J.W., Stern M.P., Van de Berg J.F., Haffner S.M. Effects of NIDDM on lipoprotein(a) size. Diabetes. 43:1994;942-946.
63. Chang C.J., Kao J.T., Wu T.J., Lu F.H., Tai T.Y. Serum lipids and lipoprotein(a) concentrations in Chinese NIDDM patients. Relation to metabolic control. Diabetes Care. 18:1995;1191-1194.
64. Grafe M., Auch-Schwelk W., Hertel H., Terbeek D., Steinheider G., Loebe M., Fleck E. Human cardiac microvascular and macrovascular endothelial cells respond differently to oxidatively modified LDL. Atherosclerosis. 137:1998;87-95.
65. Valssara H. Advanced glycation end products and atherosclerosis. Ann Med. 28:1996;419-426.
66. Schmidt A.M., Hori O., Brett J., Yan S.D., Wautier J-L., Stern D. Cellular Receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb. 14:1994;1521-1528.